To date, 10% FCS continues to be the most common media supplement employed in clinical trials for kidney disease, although some consideration has been given to the use of xenogeneic-free media such as hPL (5 or 10%), human serum albumin (HSA) and a CDM (Table 2). This evidence concerns the gene ALB and kidney disorder.